Compare Monolithic Power Systems Inc (MPWR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Novo Nordisk A/S — how do they compare? Monolithic Power Systems Inc trades at $1,397.04 (market cap $67.32B), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.5× Monolithic Power Systems Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Novo Nordisk A/S for 116 Days on average.
| MPWR | NVO | |
|---|---|---|
Market Cap | $67.32B | $165.31B |
Volume | 826,960 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $1.69K | $63.98 |
52-Week Low | $856.96 | $35.29 |
Typical Hold Time | 25 Days | 116 Days |
Enterprise Value | $65.92B | $179.56B |
Dividend Yield | 0.58% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,425.98, down 3.24% today but maintains strong technical momentum with bullish moving averages and key support at $1,417. The company demonstrates robust fundamentals with 24.5% net margins and consistent earnings beats, while expanding manufacturing capacity through the GlobalFoundries partnership announced September 9, 2026. Analyst sentiment remains overwhelmingly positive with 88% buy ratings and a $1,830 consensus price target representing 28% upside potential.
MPWR presents compelling growth exposure to AI infrastructure demand but carries premium valuation risks. The stock's 83.6 P/E ratio requires sustained high growth execution, while insider selling and competitive pressures warrant monitoring. Current technical positioning near pivot point resistance at $1,427 suggests near-term consolidation before potential breakout toward analyst targets.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
